"Designing Growth Strategies is in our DNA"

Graft versus Host Disease (GvHD) Treatment Market Size, Share and Global Trend By Type (Acute Graft Versus Host Disease (aGvHD), Chronic Graft Versus Host Disease (cGvHD)), By Treatment (mTOR Inhibitors, Tyrosine Kinase Inhibitors, Monoclonal Antibodies, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography Forecast till 2021-2028

Region : Global | Report ID: FBI101006 | Status : Ongoing

 

KEY MARKET INSIGHTS

Graft versus host disease (GvHD) is a condition that occurs after an allogeneic bone marrow or stem cell transplant. Graft versus host disease (GvHD) is a potentially serious disease, which occurs after transplantation with a genetically different individual. Graft versus host disease (GvHD) is classified into two types acute graft versus host disease (aGvHD) and chronic graft versus host disease (cGvHD).

As a recipient of the transplantation process, the individual may be diagnosed with both types, either type or none of the types. Some of the symptoms of the disease include skin rash, gastrointestinal (GI) tract disorders, and others. The individuals or the factors who are at the most risk of being diagnosed with the disease include HLA mismatch, aged recipient, female donor to male recipient and donor lymphocyte infusion.

To gain extensive insights into the market, Request for Customization


Increasing prevalence of graft versus host disease (GvHD), predominantly arising from an increasing number of allogenic transplantations is presenting a large patient pool requiring treatment. This is one of the major factors driving the growth of the global graft versus host disease (GvHD) treatment market.

Also, an increasing number of product approvals for the treatment of graft versus host disease (GvHD) and increased disease diagnosis rate are some of the factors driving the growth of the global graft versus host disease (GvHD) treatment market. According to The Leukemia & Lymphoma Society (LLS), chronic graft versus host disease (GvHD) can occur in 30-70 percent of patients receiving allogeneic transplantation.


The factors limiting the growth of the global graft versus host disease (GvHD) treatment market are the high cost of the treatment and high investment in the clinical trials. According to the studies published by the American Society of Hematology, patients who develop Acute GvHD experience over the US $100,000 more in total healthcare costs-and nearly three additional weeks in the hospital.


Key Players Covered


Some of the major companies that are present in the global graft versus Host Disease (GvHD) treatment market are Genzyme Corporation, Novartis AG, Pfizer Inc., Astellas Pharma Inc., Merck KGaA, Incyte Corporation, and others.


SEGMENTATION 


























SEGMENTATION



 DETAILS



By Type



· Acute Graft Versus Host Disease (aGvHD)


· Chronic Graft Versus Host Disease (cGvHD)



By Treatment



· mTOR Inhibitors


· Tyrosine Kinase Inhibitors


· Monoclonal Antibodies


· Others



By Distribution Channel



· Hospital Pharmacies


· Retail Pharmacies


· Online Pharmacies



By Geography



· North America (the USA and Canada)


· Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)


· Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)


· Latin America (Brazil, Mexico and Rest of Latin America)


· Middle East & Africa (South Africa, GCC and Rest of the Middle East & Africa)



 


In 2018, among disease indication, chronic graft versus host disease (cGvHD) dominated the global graft versus host disease (GvHD) treatment market due increasing prevalence and occurrence of the chronic graft versus host disease. This segment is projected to grow at comparatively higher CAGR during the forecast period.


Key Insights



  • Prevalence of Graft versus Host Disease, By Key Regions

  • Pipeline Analysis

  • Recent Industry Developments Such as Partnerships, Mergers, and Acquisitions


Regional Analysis


North America dominated the global graft versus host disease (GvHD) treatment market in 2018. Increasing prevalence of the graft versus host disease in the region is anticipated to drive the growth of the graft versus host disease (GvHD) treatment market. For instance, according to a research study published by the National Center of Biotechnology Information in 2018, suggests that around 30% to 50% of hematopoietic stem cell transplant (HSCT) recipients develop acute GVHD. That interprets to 5500 patients/year who will develop acute graft versus host disease. Eventually, around 50% of patients with acute graft versus host disease have manifestations of chronic graft versus host disease. The graft versus host disease treatment market in Europe is also anticipated to grow at a significant CAGR due to an increased prevalence of cancer, improvements in medical research, and the increasing number of players and research institutes engaged in clinical trials for new drugs/treatment options for GvHD.


Key Industry Developments



  • In May 2019, Incyte Corporation received FDA approval for ruxolitinib (Jakafi) for the treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients.
  • In February 2016, JCR Pharmaceuticals Co. Ltd., launched mesenchymal stem cell product TEMCELL HS Inj., for the treatment of acute graft versus host disease (aGVHD) in children and adults in Japan. TEMCELL is the first allogeneic cell therapy to be fully approved in Japan.

Graft versus Host Disease Treatment Market Size, Share and Global Industry Trend Forecast till 2026
  • Ongoing
  • 2020
  • 2017-2019

    CHOOSE LICENSE TYPE

  • 4850
    6850
    8850

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Healthcare Clients

Pfizer
abbvie
Roche
Jubilant
Ansell

Client Testimonials

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . More info.
X